Consistent with our hypothesis, the activation of hepatic FXR effectively offset the NAFLD phenotype and insulin resistance induced by Zbtb18 silencing, suggesting a novel yet essential role for FXR as the mediator of hepatic Zbtb18’s key functions in maintaining glucose and lipid balance. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.